TORONTO, June 17, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“ Silo Wellness” or “the Company”) (CSE: SILO) (FRA: 3K70) (OTC: SILFF), a functional and psilocybin mushroom company offering psychedelic wellness retreats, and Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction…


Previous articleMYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics
Next articleDiamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial